The Russian pharmaceutical and healthcare industry is a strategically important sector for investment. The Russian pharmaceutical market demonstrated substantial growth in 2024, increasing by 10.6% compared to 2023 to reach RUB 2.85 trillion. Under current government policies, the market is projected to reach RUB 3.76 trillion by 2030. This growth is driven by factors including the implementation of government programs, increasing demand for affordable and quality healthcare, and a significant expansion of local production.
Foreign investor interest, particularly from China and India, is increasing, creating further opportunities for international collaboration.
The implementation of pharmaceutical and healthcare projects in Russia is occurring amidst significant regulatory changes, including recent amendments to public procurement legislation, compulsory licensing considerations, increased competition safeguards, and the ongoing development of regulatory frameworks within the Eurasian Economic Union (EAEU). In light of these developments, comprehensive legal due diligence of assets and transactions is critical for successful investment in the sector. We provide specialized legal counsel to navigate these complexities and support our clients’ investment goals.
